Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2017

View Archived Issues

GD116 demonstrates enhanced antitumor efficacy in human breast cancer models

U.S. Dept. of Health & Human Services describes FLT3-specific chimeric antigen receptors

EpiVax receives grant to develop therapy for Graves disease

Promising phase I data for CK-2127107 in healthy subjects

Rhizen's tenalisib given orphan drug designation for peripheral T-cell lymphoma

FDA gives Cu(II)-ATSM orphan drug status for ALS

Eloxx Pharmaceuticals and Sevion Therapeutics complete acquisition

JSR Corporation to acquire Crown Bioscience International

Novel SCN2A gene mutations tied to intractable epilepsy

First clinical results reported for CAR T cells targeting CD123

Ticagrelor well tolerated in phase II pediatric sickle cell disease trial

Loxo Oncology starts rolling NDA submission for larotrectinib

TARIS and BMS agree to test combination therapy for muscle invasive bladder cancer

Arrowhead Pharmaceuticals applies to conduct first-in-human study of ARO-AAT

Cadent Therapeutics identifies novel potassium channel modulators

New parkin modulators divulged by An2H Discovery

The University of Texas discloses novel SHP-2 inhibitors

NuCana BioMed discovers new cladribine derivatives

FDA approves Macrilen for diagnosis of adult growth hormone deficiency

FDA expands Opdivo indication

FDA approves Perjeta for adjuvant treatment of HER2-positive early breast cancer

AbbVie reports topline results from phase III study of upadacitinib

Aivita initiates phase II autologous cancer immunotherapy study in ovarian cancer

FDA grants QIDP designation to ceftobiprole for S. aureus bacteremia

FDA accepts Seysara NDA for moderate to severe acne

UCB reports phase IIb data on bimekizumab in psoriatic arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...